Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) Short Interest Update

Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) was the target of a large decrease in short interest in the month of March. As of March 13th, there was short interest totaling 12,677 shares, a decrease of 70.1% from the February 26th total of 42,416 shares. Based on an average daily trading volume, of 71,894 shares, the days-to-cover ratio is presently 0.2 days. Approximately 1.9% of the company’s stock are short sold. Approximately 1.9% of the company’s stock are short sold. Based on an average daily trading volume, of 71,894 shares, the days-to-cover ratio is presently 0.2 days.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. Wall Street Zen raised Biodexa Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 3.5%

Shares of BDRX stock opened at $0.66 on Wednesday. Biodexa Pharmaceuticals has a 12-month low of $0.65 and a 12-month high of $19.30. The business’s 50 day moving average is $1.34 and its two-hundred day moving average is $3.99.

Biodexa Pharmaceuticals shares are going to reverse split on Monday, April 6th. The 1-5 reverse split was announced on Wednesday, March 18th. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, April 3rd.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Biodexa Pharmaceuticals stock. Armistice Capital LLC acquired a new position in shares of Biodexa Pharmaceuticals PLC Unsponsored ADR (NASDAQ:BDRX) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 100,000 shares of the company’s stock, valued at approximately $227,000. Armistice Capital LLC owned 14.71% of Biodexa Pharmaceuticals as of its most recent filing with the SEC. 17.51% of the stock is owned by institutional investors.

Biodexa Pharmaceuticals Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.